SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G/A
 
Under the Securities Exchange Act of 1934
(Amendment No.  3)*
 

Kiniksa Pharmaceuticals, Ltd.

(Name of Issuer)
 

Class A Common Shares, par value $0.000273235 per share

(Title of Class of Securities)
 

G5269C101

(CUSIP Number)
 

December 31, 2022

(Date of Event Which Requires Filing of This Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
ý Rule 13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 5 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. G5269C10113G/APage 2 of 5 Pages

 

1

NAME OF REPORTING PERSON

HHLR Advisors, Ltd.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

2,623,924 Class A Common Shares

6

SHARED VOTING POWER

-0-

7

SOLE DISPOSITIVE POWER

2,623,924 Class A Common Shares

8

SHARED DISPOSITIVE POWER

-0-

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,623,924 Class A Common Shares

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.6%

12

TYPE OF REPORTING PERSON

IA

         

 

 

 

CUSIP No. G5269C10113G/APage 3 of 5 Pages

 

Item 1(a). NAME OF ISSUER
  The name of the issuer is Kiniksa Pharmaceuticals, Ltd. (the "Company").
   

 

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
  The Company's principal executive office is located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.
   
Item 2 (a). NAME OF PERSON FILING
  This statement is filed by HHLR Advisors, Ltd., an exempted Cayman Islands company (“HHLR” or the “Reporting Person”), with respect to the Class A Common Shares (as defined in Item 2(d) below) held by HHLR Fund, L.P. (“HHLR Fund”).  HHLR acts as the sole investment manager of HHLR Fund.  HHLR is hereby deemed to be the sole beneficial owner of, and to control the voting and investment power of, the Class A Common Shares held by HHLR Fund.  
   
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
  The address of the business office of the Reporting Person is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, KY1-9006.
   
  Item 2(c). CITIZENSHIP
    Cayman Islands
     
Item 2(d). TITLE OF CLASS OF SECURITIES
  Class A Common Shares, par value $0.000273235 per share (the "Class A Common Shares").
   
Item 2(e). CUSIP NUMBER
  G5269C101
   
Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
  (a) ¨ Broker or dealer registered under Section 15 of the Act;
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
  (e) ý An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
  (f) ¨

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

 

  (g) ¨

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 

         

 

CUSIP No. G5269C10113G/APage 4 of 5 Pages

 

  (h) ¨

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

  (i) ¨

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

  (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution: _______________________________

   
Item 4. OWNERSHIP
  The percentage set forth in this Schedule 13G/A is calculated based upon an aggregate of 34,531,084 Class A Common Shares outstanding as of October 31, 2022, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 filed with the Securities and Exchange Commission on November 3, 2022.
   
  The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.
   
Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
  Not applicable.
   
Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
  See Item 2.
   
Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON  
  Not applicable.  
     
Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP  
  Not applicable.  
     
Item 9. NOTICE OF DISSOLUTION OF GROUP  
  Not applicable.  
     
Item 10. CERTIFICATION  
  The Reporting Person hereby makes the following certification:
   
  By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

CUSIP No. G5269C10113G/APage 5 of 5 Pages

 

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATE: February 14, 2023

 

HHLR Advisors, LTD.  
   
   
/s/ Audrey Woon  
Name: Audrey Woon  
Title: Chief Compliance Officer